(Q37636722)

21 August 2017

1 reference

title

Drug development for orphan diseases in the context of personalized medicine (English)

1 reference

21 August 2017

1 reference

personalized medicine

1 reference

George J Brewer

1

1 reference

21 August 2017

publication date

23 April 2009

1 reference

21 August 2017

published in

Translational Research

1 reference

21 August 2017

volume

154

1 reference

21 August 2017

issue

6

1 reference

21 August 2017

page(s)

314-322

1 reference

Does orphan drug legislation really answer the needs of patients?

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.03.008

Wilson disease: genetic basis of copper toxicity and natural history

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.03.008

Oral zinc therapy for Wilson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.03.008

Treatment of Wilson's disease with zinc. I. Oral zinc therapy regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.03.008

Treatment of Wilson's disease with zinc XII: dose regimen requirements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.03.008

Treatment of Wilson's disease with zinc: XI. Interaction with other anticopper agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.03.008

Treatment of Wilson's disease with zinc: XIV. Studies of the effect of zinc on lymphocyte function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.03.008

The treatment of Wilson's disease with zinc. IV. Efficacy monitoring using urine and plasma copper

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.03.008

Treatment of Wilson's disease with zinc. XVII: treatment during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.03.008

Treatment of Wilson's disease with zinc XVI: treatment during the pediatric years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.03.008

Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.03.008

An investigation of the effects of intravenous administration of thiomolybdate on copper metabolism in chronic Cu-poisoned sheep

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.03.008

Copper metabolism in rats given di- or trithiomolybdates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.03.008

Effects of molybdate, sulfide, and tetrathiomolybdate on copper metabolism in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.03.008

Copper and molybdenum absorption by rats given ammonium tetrathiomolybdate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.03.008

Initial therapy of patients with Wilson's disease with tetrathiomolybdate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.03.008

Treatment of Wilson Disease With Ammonium Tetrathiomolybdate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.03.008

Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.03.008

A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.03.008

Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.03.008

A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.03.008

Fundamental problems lie ahead in the drug discovery and commercialization process: restructuring of the pharmaceutical industry and an improved partnership with academia are required

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSL.2009.03.008

10.1016/J.TRSL.2009.03.008

7 January 2021

Identifiers

DOI

1 reference

21 August 2017

1 reference